|
| 1 |
|
Additional conditions recognized in this trial |
|
|
Astrocytoma |
|
|
Central Nervous System Neoplasms |
|
|
Nervous System Neoplasms |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
| 2 |
|
More general conditions related to this trial |
|
|
Glioma |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
|
Nervous System Diseases |
|
| 3 |
|
Interventions listed in this trial |
|
|
leucovorin calcium |
|
|
mechlorethamine hydrochloride |
|
|
methotrexate |
|
|
prednisone |
|
|
procarbazine hydrochloride |
|
|
vincristine sulfate |
|
|
conventional surgery |
|
| 4 |
|
Additional drug interventions recognized in this trial |
|
|
Leucovorin |
|
|
Mechlorethamine |
|
|
Procarbazine |
|
|
Vincristine |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Abortifacient Agents |
|
|
Abortifacient Agents, Nonsteroidal |
|
|
Alkylating Agents |
|
|
Anti-Inflammatory Agents |
|
|
Antimetabolites |
|
|
Antimetabolites, Antineoplastic |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antineoplastic Agents, Hormonal |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Antirheumatic Agents |
|
|
Dermatologic Agents |
|
|
Enzyme Inhibitors |
|
|
Folic Acid Antagonists |
|
|
Glucocorticoids |
|
|
Growth Substances |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Micronutrients |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Nucleic Acid Synthesis Inhibitors |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Reproductive Control Agents |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
|
Vitamin B Complex |
|
|
Vitamins |
|
| 6 |
|
Sponsors listed in this trial |
|
|
M.D. Anderson Cancer Center |
